• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾细胞癌中的肿瘤抗原和标志物

Tumor antigens and markers in renal cell carcinoma.

作者信息

Mulders Peter, Bleumer Ivar, Oosterwijk Egbert

机构信息

Department of Urology, University Medical Center Nijmegen, Geert Grooteplein 10, 6500 HB Nijmegen, The Netherlands.

出版信息

Urol Clin North Am. 2003 Aug;30(3):455-65. doi: 10.1016/s0094-0143(03)00024-7.

DOI:10.1016/s0094-0143(03)00024-7
PMID:12953748
Abstract

Tumor markers are mainly used to diagnose specific malignancies. The methods commonly involve immunohistochemistry and cytogenetics, including FISH and RT-PCR. In RCC, the investigated tumor markers (summarized in Table 1) show additional prognostic value over classical prognostic factors such as stage and grade. These markers can be used for better patient selection, a more accurate individualization of treatment, and improved follow-up. Nevertheless, their definitive value must be reconfirmed in larger patient cohorts. Ultimately, these factors should be shown to be of value in a prospective well-controlled trial. One of the most promising new techniques involves gene expression profiling of solid tumors. This cDNA microarray technique applied in RCC has improved understanding of the molecular mechanism of the underlying tumor genesis and its correlation to the clinical course. Tumor antigens that are specific for RCC (eg, G250) and that induce a specific immune response can be used for vaccine treatment modalities. With the use of dendritic cells, antigen presentation can be improved. Several phase I studies are currently underway. More research is needed to obtain better antigens and markers in RCC to improve insight into the molecular mechanism of the development of RCC, to improve the selection of patients for treatment, and to increase its effectiveness.

摘要

肿瘤标志物主要用于诊断特定的恶性肿瘤。常用方法包括免疫组织化学和细胞遗传学,其中包括荧光原位杂交(FISH)和逆转录聚合酶链反应(RT-PCR)。在肾细胞癌(RCC)中,所研究的肿瘤标志物(总结于表1)显示出比诸如分期和分级等经典预后因素更高的预后价值。这些标志物可用于更好地选择患者、更准确地进行个体化治疗以及改善随访。然而,它们的确切价值必须在更大的患者队列中重新得到证实。最终,这些因素应在一项前瞻性的严格对照试验中证明其价值。最有前景的新技术之一涉及实体瘤的基因表达谱分析。应用于肾细胞癌的这种cDNA微阵列技术增进了对潜在肿瘤发生分子机制及其与临床病程相关性的理解。对肾细胞癌具有特异性(例如G250)并能诱导特异性免疫反应的肿瘤抗原可用于疫苗治疗模式。通过使用树突状细胞,可以改善抗原呈递。目前正在进行几项I期研究。需要开展更多研究以获得更好的肾细胞癌抗原和标志物,从而增进对肾细胞癌发生发展分子机制的认识,改善治疗患者的选择,并提高其有效性。

相似文献

1
Tumor antigens and markers in renal cell carcinoma.肾细胞癌中的肿瘤抗原和标志物
Urol Clin North Am. 2003 Aug;30(3):455-65. doi: 10.1016/s0094-0143(03)00024-7.
2
Prognostic histological and immune markers of renal cell carcinoma.肾细胞癌的预后组织学和免疫标志物
Pathol Oncol Res. 2001;7(2):118-24. doi: 10.1007/BF03032577.
3
MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas.MN/CA IX/G250作为肾细胞癌免疫治疗的潜在靶点。
Br J Cancer. 1999 Oct;81(4):741-6. doi: 10.1038/sj.bjc.6690757.
4
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.肾细胞癌中的碳酸酐酶 IX:对预后、诊断和治疗的影响。
Eur Urol. 2010 Jul;58(1):75-83. doi: 10.1016/j.eururo.2010.03.015. Epub 2010 Mar 23.
5
Evaluation of morphologically unclassified renal cell carcinoma with electron microscopy and novel renal markers: implications for tumor reclassification.应用电子显微镜和新型肾脏标志物评估形态学未分类的肾细胞癌:对肿瘤重新分类的意义
Ultrastruct Pathol. 2013 Feb;37(1):70-6. doi: 10.3109/01913123.2012.739595.
6
Prognostic significance of extensive necrosis in renal cell carcinoma.肾细胞癌广泛坏死的预后意义
Hum Pathol. 2017 Aug;66:108-114. doi: 10.1016/j.humpath.2017.06.010. Epub 2017 Jun 29.
7
Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.COX - 1与VEGF免疫组化联合应用可优化肾细胞癌的组织病理学预后。
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8165-77. eCollection 2015.
8
Categorizing renal oncocytic neoplasms on core needle biopsy: a morphologic and immunophenotypic study of 144 cases with clinical follow-up.在粗针活检中对肾嗜酸细胞瘤进行分类:一项对144例病例的形态学和免疫表型研究及临床随访
Hum Pathol. 2016 Sep;55:1-10. doi: 10.1016/j.humpath.2016.03.017. Epub 2016 Apr 13.
9
The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.PAX-2在鉴别转移性透明细胞肾细胞癌与其形态学类似物中的应用:一项与肾细胞癌标志物对比的免疫组化研究
Am J Surg Pathol. 2008 Oct;32(10):1462-7. doi: 10.1097/PAS.0b013e318176dba7.
10
Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability.肾细胞癌的诊断和预后分子标志物:对当前研究现状及临床适用性的批判性评估
Eur Urol. 2009 Apr;55(4):851-63. doi: 10.1016/j.eururo.2009.01.003. Epub 2009 Jan 13.

引用本文的文献

1
Comparison of circulating and intratumoral regulatory T cells in patients with renal cell carcinoma.肾细胞癌患者循环和肿瘤内调节性T细胞的比较。
Tumour Biol. 2015 May;36(5):3727-34. doi: 10.1007/s13277-014-3012-8. Epub 2015 Jan 7.
2
Construction of humanized carcinoembryonic antigen specific single chain variable fragment and mitomycin conjugate.人源化癌胚抗原特异性单链可变片段与丝裂霉素缀合物的构建
World J Gastroenterol. 2007 Nov 21;13(43):5765-70. doi: 10.3748/wjg.v13.i43.5765.
3
CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy.
CA9基因在传统型肾细胞癌中的表达:肾切除术后早期转移预测的潜在标志物。
Clin Exp Metastasis. 2007;24(3):149-55. doi: 10.1007/s10585-007-9064-z. Epub 2007 Mar 28.
4
Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.使用或不使用环磷酰胺的异基因树突状细胞疫苗接种治疗转移性肾细胞癌
Cancer Immunol Immunother. 2005 Jul;54(7):663-70. doi: 10.1007/s00262-004-0629-2. Epub 2004 Dec 17.
5
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.人肾损伤分子-1是肾细胞癌的一种组织和尿液肿瘤标志物。
J Am Soc Nephrol. 2005 Apr;16(4):1126-34. doi: 10.1681/ASN.2004070530. Epub 2005 Mar 2.